Ambu A/s Class B · OMXCOP:AMBU_B

Ambu A/s Class B — Q3 2021/22 Earnings Presentation

9 slides from Ambu A/s Class B's earnings presentation, Aug 4, 2022

  1. Slide 1: Preliminary Results for Q3 2021/22, Current Trading (July) and Launch of Cost Reduction Program

    PRELIMINARY RESULTS FOR Q3 2021/22, CURRENT TRADING (JULY) AND LAUNCH OF COST REDUCTION PROGRAM. FULL-YEAR 2021/22 GUIDANCE REVISED AUGUST 4, 2022

  2. Slide 2: Today's Speakers

    TODAY’S SPEAKERS BRITT MEELBY JENSEN THOMAS FREDERIK SCHMIDT CEO CFO

  3. Slide 3: Executive Summary

    EXECUTIVE SUMMARY 1 PRELIMINARY RESULTS FOR Q3 2021/22 Ambu achieved 8% organic revenue growth. Visualization organic revenue growth was 0% while Anaesthesia posted 14% and PMD 20% 2 LAUNCH OF COST REDUCTION PROGRAM Cost reduction program launched to strengthen our financial position and flexibility

  4. Slide 4: Financial Highlights for Q3 2021/22

    FINANCIAL HIGHLIGHTS FOR Q3 2021/22 Financial performance for Q3 2021/22 Performance highlights GROUP GROSS ORGANIC GROWTH MARGIN Gross margin for Q3 has been negatively impacted by inflationary effect on inputs prices, ramp up of Mexico plant 8% 55.8% and unfavourable product mix VISUALIZATION EBIT

  5. Slide 5: Preliminary Financials for Q3 2021/22

    PRELIMINARY FINANCIALS FOR Q3 2021/22 DKKm (reported figures) Q3 2021/22 Q3 2020/21 Change Revenue 1,128 973 +16% Gross profit 629 608 +3% Gross margin 55.8% 62.5% -6.7%-pts Capacity costs 587 520 +12% EBIT 42 88 -52% before special items EBIT margin 3.7% 9.0% -5.3%-pts before special items Special

  6. Slide 6: Launch of Cost Reduction Program

    LAUNCH OF COST REDUCTION PROGRAM STRENGTHENING OUR FINANCIAL POSITION AND FLEXIBILITY Previous expectations to our financial performance have not been met, and it has, after assessing the current situation, become clear that the market creation in single- use endoscopy is taking longer than previous

  7. Slide 7: Revised Financial Guidance 2021/22

    REVISED FINANCIAL GUIDANCE 2021/22 1 Previous guidance assumed rapid Q4 growth, however the July 4% no less than trading showed 6% organic revenue growth and was significantly below expectation leading to a revision of our guidance Organic revenue growth Organic revenue growth is revised from 13%+ t

  8. Slide 8: Q&A Session

    Q&A SESSION

  9. Slide 9: Thank You for Your Attention

    THANK YOU FOR YOUR ATTENTION 25 AUGUST: Q3 2021/22 EARNINGS ANNOUNCEMENT, COPENHAGEN 25 AUGUST: ROADSHOW IN COPENHAGEN 31 AUGUST – 1 SEPTEMBER: ROADSHOW IN FRANKFURT AND PARIS 21 SEPTEMBER: ROADSHOW IN LONDON 29 – 30 SEPTEMBER: ROADSHOW IN ZURICH AND GENEVA 5 OCTOBER: J.P. MORGAN CEO CALL SERIES 15

Ambu — Q3 2021/22 Earnings Presentation on 6ix